Welkin Health and Neurotrack Partner on New Study to Advance Solutions for Individuals At Risk for Cognitive Decline
San Francisco, CA (PRWEB) December 13, 2016 -- Welkin Health, a San Francisco-based company that helps build digital therapeutics on its platform, has partnered with Neurotrack, a digital health company focused on the early detection of cognitive decline and prevention of diseases like Alzheimer’s.
A 6-month clinical study will utilize Welkin Health coaches to support Neurotrack’s cognitive assessment and lifestyle program designed to help individuals at risk for cognitive decline. Welkin’s configurable platform will enable the study team to engage, track and measure cognitive health outcomes of individuals over time to determine the effectiveness of early detection and lifestyle programs using Neurotrack’s technology.
“More than 16 million Americans live with cognitive impairment, and more than five million have Alzheimer’s, with that number expected to grow as baby boomers age,” says Elli Kaplan, CEO and co-founder of Neurotrack. “Changes in lifestyle can alter the course of cognitive decline, improve outcomes, and reduce many of the significant costs associated with cognitive disease. With Welkin’s platform and coaches supporting our study, people will receive the guidance, ongoing support and engagement, to ensure that individuals have the resources necessary to stay with the program and ultimately improve their own health.”
Designed specifically to meet the needs of the study, Welkin’s platform will enable health coaching support through workflow prompts, built-in communication tools, and insights delivered from third-party integrations. Collectively, this will allow the Neurotrack team to monitor a person’s progress and measure health outcomes over the course of the study.
Neurotrack’s Imprint™ Check-Up utilizes a patent-pending eye-tracking technology to determine an individual’s future risk for cognitive decline. Once risk is identified, Neurotrack works to emphasize lifestyle changes such as diet, exercise, sleep, stress management and cognitive training, all shown to have measurable impact on brain function. Neurotrack and Welkin Health, both Rock Health portfolio companies, will receive enrollment and data analytics support from a third Rock Health company, Evidation Health, making this the first three-way collaboration in the portfolio.
“Viable solutions to offset the severe challenges that can come with cognitive decline are greatly needed,” says Chase Hensel, CEO and co-founder, Welkin Health. “Neurotrack’s technology is providing a promising solution by focusing on cognitive decline. We are hopeful that this study will show that coaching integrated with a cognitive health program will have a positive impact, changing the future for those at risk for cognitive decline.”
About Welkin Health
Welkin Health is a digital health company that helps healthcare organizations improve health outcomes and reduce operational costs through engagement, education, and support programs for people living with chronic disease. Our workflow and communication software, customized for each partner, allows care teams to prioritize patient outreach and reach individuals on any device, including SMS, phone call, and email. Welkin helps teams focus on building and maintaining long-term relationships with custom configurations of the Welkin patient relationship management platform.
About Neurotrack
Neurotrack is a digital health company that is changing the way consumers and the medical community address cognitive health.
Neurotrack provides science-based, memory health assessment tools that help prevent cognitive decline, which is often a precursor of dementia and Alzheimer’s. Neurotrack’s proprietary Imprint Check-Up, a five-minute, computer-based cognitive assessment that tracks eye movements to detect abnormalities in the hippocampus that are indicators of cognitive impairment. The Imprint Check-Up is backed by 30 years of scientific research, and is the only cognitive assessment tool available that can detect risk of memory loss years before symptoms appear.
Neurotrack is led by CEO and cofounder Elli Kaplan, and scientific co-founders Stuart Zola,
PhD, Elizabeth Buffalo, PhD, and Cecelia Manzanarez, leaders in the fields of neuroscience and Alzheimer’s disease.
For more information and to access Neurotrack’s brain health assessment tools and programs, visit http://www.neurotrack.com.
Ashley Greer, Welkin Health, +1 (760) 485-0149, [email protected]
Share this article